The Gamma Building
Ideongatan 1
Lund 223 70
Sweden
46 4 62 86 85 50
https://www.bioinvent.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 103
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Martin Welschof Ph.D. | Pres & CEO | 5,06M | N/D | 1961 |
Mr. Stefan Ericsson M.B.A. | Chief Financial Officer | N/D | N/D | 1963 |
Ms. Marie Moores M.Sc., R.G.N. | Chief Operating Officer | N/D | N/D | N/D |
Mr. Kristoffer Rudenholm Hansson | Sr. VP of Technical Operations | N/D | N/D | 1974 |
Mr. Björn Frendéus | Chief Scientific Officer | N/D | N/D | 1973 |
Ms. Cecilia Hofvander | Sr. Director of Investor Relations | N/D | N/D | 1967 |
Dr. Andres McAllister | Chief Medical Officer | N/D | N/D | 1956 |
Ms. Ingrid Teige | Head of Preclinical Research | N/D | N/D | N/D |
Ms. Sylvie Ryckebusch | Chief Bus. Officer | N/D | N/D | N/D |
Dr. Ingunn Munch Lindvig | Sr. VP of Regulatory Affairs | N/D | N/D | N/D |
BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. Its drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells; cancer-associated regulatory T cells, which modulate the immune system; BT-001 for solid tumors; and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma. It has a partnership and collaboration with Transgene to co-develop BT-001 multi-functional oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck to evaluate BT-001 in combination with Keytruda, and in BI-1808. BioInvent International AB (publ) was incorporated in 1996 and is based in Lund, Sweden.
L'ISS Governance QualityScore di BioInvent International AB (publ) al 1 ottobre 2023 è 5. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 2; diritti degli azionisti: 1; retribuzione: 9.